Objective: This study was undertaken to determine the acute effects of a commercial weight loss supplement containing herbal ephedrine and caffeine on cardiovascular function in healthy overweight adults.
Design: Randomized double blind clinical trial evaluating the cardiovascular effects of an ephedra–caffeine (XenadrineTM; XEN) based herbal product vs placebo (PLA).
Subjects: Twenty-seven healthy overweight adults (age 21–60 y; body mass index ≥25 kg/m2).
Measurements: Systolic and diastolic blood pressure, heart rate, serial electrocardiograms (EKG) and Doppler echocardiograms.
Results: A comparison of means between the groups indicated no statistically significant differences at the start of the study for the variables above. There were no serious adverse events. When examining the effects of XEN vs PLA on cardiovascular health/function, there were no significant effects observed in heart rate, systolic blood pressure, diastolic blood pressure, left ventricular ejection fraction, heart valve function or in cardiovascular physiology within the parameters measured.
Conclusion: These findings indicate that, over a 14-day period, ingestion of the commercial weight loss supplement in a healthy overweight population did not produce any noticeable cardiovascular side effects.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Haller CA, Benowitz NL . Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedrine alkaloids New Engl J Med 2000 242: 1833–1838.
Schaefer DC, Cheskin LJ . Update on obesity treatment Gastroenterologist 1998 6: 136–145.
National Institute of Health, National Heart, Lung and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults US Department of Health and Human Services, Public Health Services: Washington, DC 1998.
Astrup A, Madsen J, Holst JJ, Christensen NJ . The effect of chronic ephedrine treatment on substrate utilization, the sympathoadrenal activity, and energy expenditure during glucose induced thermogenesis in man Metabolism 1986 35: 260–265.
Jacob LS . Drugs affecting peripheral neurohumoral transmission: sympathomimetic agents In Pharmacology 4th Edn Williams & Wilkins: Baltimore, MD 1996 p 28.
Greenway FL . The safety and efficacy of pharmaceutical and herbal caffeine and ephedrine use as a weight loss agent Obes Rev 2001 2: 199–211.
Dulloo AG, Miller DS . The thermogenic properties of ephedrine/methylxanthine mixtures: human studies Int J Obes 1986 10: 467–481.
Boozer CN, Nasser JA, Heymsfield SB, Wang V, Chen G, Solomon JL . An herbal supplement containing Ma Huang-Guarana for weight loss: a randomized, double blind trial Int J Obes Relat Metab Disord 2001 25: 316–324.
Kalman DS, Colker CM, Shi Q, Swain MA . Effects of a weight loss aid in healthy overweight adults: a double blind clinical trial Curr Ther Res 2000 61: 199–207.
Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L . Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity Int J Obes Relat Metab Disord 1993 17: s73–s78.
Astrup A, Tourbo S . Thermogenic, metabolic and cardiovascular responses to ephedrine and caffeine in man Int J Obes Relat Metab Disord 1993 17: s41–43.
Waluga M, Janusz M, Karpal E, Hartleb M, Nowak A . Cardiovascular effects of ephedrine, caffeine and yohimbine measured by thoracic electrical bioimpedance in obese women Clin Physiol 1998 18: 69–76.
Penzak SR, Jann MW, Cold JA, Hon YY, Desai HD, Gurley BJ . Seville orange juice: synephrine content and cardiovascular effects in normotensive adults J Clin Pharmac 2001 41: 1059–1063.
Pedersen KJ, Kuntz DH, Garbe GJ . Acute myocardial ischemia associated with ingestion of bupropion and pseudoephedrine in a 21-year old man Can J Cardiol 2001 17: 599–601.
Palinkas A, Picano E, Rodriguez O, Diordjevic-Dikic A, Landi P, Varga A, Ghelarducci B . Safety of ergot stress echocardiography for non-invasive detection of coronary vasospasm Coron Artery Dis 2001 12: 649–654.
Tun A, Khan IA . Myocardial infarction with normal coronary arteries: the pathologic and clinical perspectives Angiology 2001 52: 299–304.
Bray GA . Pharmacological treatment of obesity In: Bray GA, Bouchard C, James WPT (eds) Handbook of obesity Marcel Dekker: New York 1998 pp 876–953.
Funding for this study was provided by Cytodyne Technologies.
About this article
Cite this article
Kalman, D., Incledon, T., Gaunaurd, I. et al. An acute clinical trial evaluating the cardiovascular effects of an herbal ephedra–caffeine weight loss product in healthy overweight adults. Int J Obes 26, 1363–1366 (2002). https://doi.org/10.1038/sj.ijo.0802061
This article is cited by
International Journal of Obesity (2004)